Are the new class of GLP1 anti-obesity medications a panacea?
Are the new class of GLP1 anti-obesity medications a panacea?
GLP1R agonists, including semaglutide (Ozempic) and tirzepatide (Mounjaro) are hugely effective in the treatment of obesity. Originally developed for Type 2 diabetes, these drugs also cause dramatic weight loss. But how do they work, and are these therapeutics the long sought after solution to obesity? Join Professor Giles Yeo as he explains the mechanisms of action of these drugs, and discuss their importance as a therapeutic for obesity, type 2 diabetes, and heart disease, and crucially, whether they are safe in the long term.
Speaker
Professor Giles Yeo (Wolfson 1994)
Giles Yeo, a Cambridge PhD graduate in molecular genetics (1998), worked under Professor Sir Stephen O’Rahilly on severe human obesity genetics. He's now a Molecular Neuroendocrinology Professor and MRC Metabolic Diseases Programme leader in Cambridge. Research spans genes' impact on feeding behaviour & body weight. Yeo's also Wolfson College fellow, British Dietetic Association Honorary President. As a BBC science documentary presenter and 'Dr Giles Yeo Chews the Fat' podcast host, he authored 'Gene Eating' (Dec 2018) and 'Why Calories Don’t Count' (Jun 2021). Awarded MBE in Queen’s 2020 birthday honours for Research, Communication, Engagement services. Society for Endocrinology Medal recipient (2022).
Reading list
Gene Eating – The story of human appetite (2018, Orion)
Why Calories Don’t Count (2021, Orion)
Booking information
In-person lectures at the Sidgwick Site as part of Alumni Festival cost £15 per person.
Location
Contact
Share this page
